

PATIENT INFORMATION Deliver Here

Patient Name: _____

DOB: _____ Gender: Male Female

Address: _____

City _____ State _____ Zip: _____

Primary Phone: _____ SSN: _____

Caregiver Name: _____

Alternate Phone: _____

PRESCRIBER INFORMATION Deliver Here

Prescriber Name: _____

State License #: _____ DEA #: _____

NPI #: _____

Address: _____

City _____ State _____ Zip: _____

Phone: _____ Fax: _____

Contact Person: _____ Phone: _____

Please fax a copy of front and back of the insurance card(s).

Clinical Information (Please fax pertinent lab information)

Diagnosis: G35 (Multiple Sclerosis) Other (ICD-10 code with description): _____ Diagnosis Date: __/__/____

Type: Primary-progressive Secondary-progressive Clinically isolated syndrome Relapsing-remitting Progressive-relapsing

Has pregnancy been excluded: Yes No Not Applicable Wt: _____ Kg lbs Ht: _____ cm in

Hepatic impairment present: Yes No AST: _____ U/L ALT: _____ U/L Bilirubin: _____ mg/dL Lab date: _____

Prior Therapy <input type="checkbox"/> Yes <input type="checkbox"/> No	Reason for Discontinuation of therapy	Start date	End Date

Allergies: NKDA Other: _____

Comorbidities: _____

Concomitant Medications: _____

Drug Dose/Strength Directions Qty Refills

LEMTRADA (alemtuzumab)				
OCREVUS (ocrelizumab)	300mg/10mL Vial	Starter Dose: Infuse 300 mg intravenously over no less than 2.5 hours on day 1 and day 15. Maintenance Dose: Infuse 600 mg intravenously over no less than 3.5 hours every 6 months.		
Premedication: Methylprednisolone Other: _____	Other: _____	Infuse 100 mg IV approximately 30 mins prior to Ocrevus Other: _____		
Premedication Diphenhydramine Other: _____	Other: _____	Other: _____		

Product substitution permitted Dispense as written

Prescriber's Signature: _____ Date: _____